Market research
2EM.F Ergomed plc
F EUR Healthcare
Latest close
As of 28 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 789M
- P/E ratio
- 44.48
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.79
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- GB00BN7ZCY67
- Market cap
- 789M
- P/E ratio
- 44.48
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 0.79
About
About Ergomed plc
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
Research context
Ergomed plc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 2EM.F discussion.
5 years, 6 months ago
Ergomed plc is currently in a long term uptrend where the price is trading 14.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.7.
Finally, its free cash flow grew by 14.6% to $5M since the same quarter in the previous year.
Based on the above factors, Ergomed plc gets an overall score of 3/5.